Cover Image

Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring

A population pharmacokinetic analysis of dalbavancin was conducted in patients with different infection sites. Non-linear mixed effect modeling was used for pharmacokinetic analysis and covariate evaluation. Monte Carlo simulations assessed the probability of target attainment (PTA) of total dalbava...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pier Giorgio Cojutti (Author), Sara Tedeschi (Author), Milo Gatti (Author), Eleonora Zamparini (Author), Marianna Meschiari (Author), Paola Della Siega (Author), Maria Mazzitelli (Author), Laura Soavi (Author), Raffaella Binazzi (Author), Elke Maria Erne (Author), Marco Rizzi (Author), Anna Maria Cattelan (Author), Carlo Tascini (Author), Cristina Mussini (Author), Pierluigi Viale (Author), Federico Pea (Author)
Format:	Book
Published:	MDPI AG, 2022-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections
by: Rossella Barone, et al.
Published: (2023)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant <i>Staphylococcus aureus</i>: A Retrospective Single-Centre Experience
by: Maria Mazzitelli, et al.
Published: (2022)

Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring
by: Rossella Barone, et al.
Published: (2023)

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring
by: Rossella Barone, et al.
Published: (2023)

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections
by: Altea Gallerani, et al.
Published: (2023)

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
by: Gatti M, et al.
Published: (2021)

Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like <i>Klebsiella pneumoniae</i> Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
by: Pier Giorgio Cojutti, et al.
Published: (2022)

Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization
by: Pier Giorgio Cojutti, et al.
Published: (2021)

A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings
by: Milo Gatti, et al.
Published: (2021)

An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> in Critically Ill Adult Patients
by: Milo Gatti, et al.
Published: (2021)

Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections
by: Milo Gatti, et al.
Published: (2021)

A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis
by: Milo Gatti, et al.
Published: (2022)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
by: Pasquale Maria Berrino, et al.
Published: (2023)

A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue
by: Matteo Conti, et al.
Published: (2024)

Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacterales</i> Bloodstream Infections and/or Ventilator-Associated Pneumonia?
by: Milo Gatti, et al.
Published: (2023)

Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP
by: Milo Gatti, et al.
Published: (2024)

Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections
by: Milo Gatti, et al.
Published: (2023)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired Pneumonia
by: Milo Gatti, et al.
Published: (2022)

Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
by: Milo Gatti, et al.
Published: (2023)

Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients
by: Carla Troisi, et al.
Published: (2023)

Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis
by: Milo Gatti, et al.
Published: (2023)

Pharmacokinetic/pharmacodynamic issues for optimizing treatment with beta-lactams of Gram-negative infections in critically ill orthotopic liver transplant recipients: a comprehensive review
by: Milo Gatti, et al.
Published: (2024)

Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against <i>Aspergillus fumigatus</i> and <i>Aspergillus flavus</i> in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
by: Pier Giorgio Cojutti, et al.
Published: (2021)

Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study
by: Pasquale Maria Berrino, et al.
Published: (2024)

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem
by: Maria Sanz Codina, et al.
Published: (2022)

Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study
by: Chun Liu, et al.
Published: (2023)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
by: Elisa Molinelli, et al.
Published: (2022)

Dalbavancin in the treatment of skin and soft tissues infection
by: Ana Candela Fajardo, et al.
Published: (2017)

Evaluating the Use of Dalbavancin for Off-Label Indications
by: Katherine Taylor, et al.
Published: (2022)

Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
by: Andrés Ruiz-Sancho, et al.
Published: (2023)

Opportunistic infections in end stage liver disease
by: Michele Bartoletti, et al.
Published: (2018)

Dalbavancin in Bone and Joint Infections: A Systematic Review
by: Sofia Lovatti, et al.
Published: (2023)

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
by: Luis Buzón-Martín, et al.
Published: (2021)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
by: Leama Ajaka, et al.
Published: (2020)

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
by: Simonetti O, et al.
Published: (2021)

Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and <i>P. aeruginosa</i>
by: Pier Giorgio Cojutti, et al.
Published: (2020)

A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections
by: Dimitra Dimopoulou, et al.
Published: (2023)

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
by: Jason W Bennett, et al.
Published: (2008)

In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
by: Mar Sánchez-Somolinos, et al.
Published: (2023)

Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience
by: Dario Cattaneo, et al.
Published: (2023)